PROPHASE LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.71 USD | -4.85% |
|
-10.46% | +4.20% |
| Apr. 16 | Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup | DJ |
| Apr. 16 | ProPhase Labs, Inc. Unveils Project ZenQ-AI | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22.8 | 106.5 | 111 | 156.8 | 81.56 | 84.99 | - | - |
| Enterprise Value (EV) 1 | 22.8 | 106.5 | 111 | 156.8 | 81.56 | 84.99 | 84.99 | 84.99 |
| P/E ratio | -7.3 x | -51 x | 17.9 x | 9.44 x | -4.61 x | -5.71 x | 9.81 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.31 x | 7.34 x | 1.4 x | 1.28 x | 1.8 x | 1.55 x | 0.61 x | 0.43 x |
| EV / Revenue | 2.31 x | 7.34 x | 1.4 x | 1.28 x | 1.8 x | 1.55 x | 0.61 x | 0.43 x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 11,574 | 11,604 | 15,486 | 16,278 | 18,045 | 18,045 | - | - |
| Reference price 2 | 1.970 | 9.180 | 7.170 | 9.630 | 4.520 | 4.710 | 4.710 | 4.710 |
| Announcement Date | 3/25/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.876 | 14.51 | 79.04 | 122.6 | 45.24 | 54.79 | 138.3 | 196.6 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -2.093 | 9.801 | 23.6 | -21.61 | -14.01 | 12.71 | 33.41 |
| Operating Margin | - | -14.42% | 12.4% | 19.24% | -47.78% | -25.58% | 9.2% | 16.99% |
| Earnings before Tax (EBT) 1 | - | -2.326 | 5.305 | 22.91 | -22.8 | -14.93 | 11.84 | 32.44 |
| Net income 1 | - | -2.125 | 6.273 | 18.46 | -16.78 | -14.93 | 11.84 | 32.44 |
| Net margin | - | -14.64% | 7.94% | 15.05% | -37.1% | -27.26% | 8.57% | 16.5% |
| EPS 2 | -0.2700 | -0.1800 | 0.4000 | 1.020 | -0.9800 | -0.8250 | 0.4800 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/15/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.472 | 45.16 | 47.53 | 29.09 | 24.2 | 21.82 | 19.3 | 13.22 | 8.365 | 4.351 | 9.86 | 11.18 | 14.92 | 18.82 | 31.13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -3.647 | 13.68 | 16.15 | 10.59 | 1.954 | -5.09 | 0.875 | -4.658 | -6.478 | -11.35 | -7.25 | -7.25 | -6.65 | -6.05 | - |
| Operating Margin | -38.5% | 30.29% | 33.97% | 36.39% | 8.07% | -23.32% | 4.53% | -35.24% | -77.44% | -260.91% | -73.53% | -64.88% | -44.56% | -32.14% | - |
| Earnings before Tax (EBT) 1 | -3.978 | 9.621 | 15.91 | 10.41 | 1.778 | -5.189 | 0.564 | -4.914 | -6.785 | -11.66 | -7.45 | -7.45 | -6.85 | -6.25 | - |
| Net income 1 | -3.978 | 10.59 | 12.49 | 7.446 | 0.969 | -2.444 | 0.55 | -3.44 | -5.141 | -8.751 | -7.45 | -7.45 | -6.85 | -6.25 | - |
| Net margin | -42% | 23.45% | 26.29% | 25.59% | 4% | -11.2% | 2.85% | -26.03% | -61.46% | -201.13% | -75.56% | -66.67% | -45.9% | -33.2% | - |
| EPS 2 | -0.2600 | 0.6600 | 0.6800 | 0.4000 | 0.0600 | -0.0800 | 0.0300 | -0.2000 | -0.3000 | -0.5100 | -0.2800 | -0.2450 | -0.1700 | -0.1300 | 0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/12/21 | 3/30/22 | 5/13/22 | 8/11/22 | 11/10/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/15/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 4.23 | - | - | - | - | - |
| Capex / Sales | - | - | 5.35% | - | - | - | - | - |
| Announcement Date | 3/25/20 | 3/31/21 | 3/30/22 | 3/28/23 | 3/15/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.20% | 84.99M | |
| -17.89% | 8.25B | |
| +39.20% | 3.57B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- PRPH Stock
- Financials ProPhase Labs, Inc.
